BioSpace News Archive

Catalyst Pharmaceuticals, Inc. announced that Patrick J. McEnany, Catalyst’s Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/Chief Operating Officer will host one-on-one meetings with investors at the 14thAnnual Citi Biotech Conference on September 4th, 2019 at the Four Seasons Boston, Massachusetts.

Zensun USA, Inc., a wholly-owned subsidiary of Zensun Sci & Tech Co. Ltd., Shanghai, announced that the investigation of NEUCARDIN, its Recombinant human neuregulin-1 fragment, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the potential treatment of Chronic Heart Failure (CHF).

St Vincent’s Institute of Medical Research in Melbourne, Australia, announced the extension of the research and licensing collaboration agreement with Janssen Pharmaceuticals, Inc, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, with focus on Alzheimer’s disease treatment.

Alcohol-Free Wipe for Eliminating Viruses and Bacteria on Personal Belongings

Adrenomed AG, the vascular integrity company, announced that its Supervisory Board has appointed two new members of the Executive Board.

Esperion announced positive top-line results from the Phase 2 bempedoic acid / ezetimibe combination tablet study.

The Award recognizes Patient Entrepreneurs demonstrating outstanding innovations which advance solutions in the prevention, management or care of cancer

A Magnetic Particle Imaging scanner will be installed in The F.M. Kirby Imaging Center at Kennedy Krieger Institute in Baltimore, Maryland.

Bittium Exhibits Its Cardiac Monitoring Products and Solutions at ESC Congress 2019

For years, companies have struggled to develop treatments for non-alcoholic fatty liver disease (NAFLD), a disease that is growing across the world and is predicted to become the main cause of chronic liver problems and the need for liver transplantation.